Top quality Pembrolizumab CAS 1374853-91-4 with best price
3 Inquiries
1374853-91-4
Pharmaceutical Grade
99.9%
Shanghai
SX
1-25kg/bag
2025-05-31
HPMC,Lithium Carbonate,Cellulose Acetate Tow,EVA resin,Terpene Resin,PP fiber
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferencePembrolizumab (brand name Keytruda) is a PD-1 inhibitor developed by Merck & Co., Ltd. It was first approved by the FDA in 2014 for the treatment of certain patients with metastatic melanoma. In 2015, the FDA approved Keytruda (pembrolizumab) for advanced non-small cell lung cancer. Subsequently, pembrolizumab was approved for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma, as first-line treatment for certain metastatic non-small cell lung cancer patients, Hodgkin's lymphoma (cHL), and certain locally advanced or metastatic urothelial carcinoma patients. In 2025, the FDA approved pembrolizumab as neoadjuvant therapy for PD-L1+ resectable locally advanced head and neck squamous cell carcinoma, and continued as adjuvant therapy in combination with radiotherapy.Basic Info
-
Product Name:
Pembrolizumab
Other Name:Pembrolizumab;Pembrolizumab (anti-PD-1);PEMBROLIMUMAB PD-1 1374853-91-4;Pembrolizumab 25mg/ml;PembrolizumabQ: What is Pembrolizumab Q: What is the CAS Number of Pembrolizumab Q: What is the storage condition of Pembrolizumab Q: What are the applications of Pembrolizumab;Research Grade Pembrolizumab(DHH02202);MK-3475;Research Grade Pembrolizumab
CAS No.:1374853-91-4
Molecular Weight:0
EC Number:807-012-2
Color/Form:Colorless to light yellow
Categories:
Characteristics-
Critical Temperature & Pressure:
Store at -80°C
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
HPMC,Lithium Carbonate,Cellulose Acetate Tow,EVA resin,Terpene Resin,PP fiber
-
Location:
Building 4, Feicui Building, No. 366 Xinshi North Road, Qiaoxi District, Shijiazhuang City, Hebei Province
-
Payment Terms:
TT against copy of documents,L/C,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
7
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
51-100
-
Year of Establishment:
2024
-
-
Inquiry History3 Inquiries
Country Product Purchase Quantity Date Posted
Netherlands
High quality Pembrolimumab/ supplier with competitive price in stock-Rechems Cas No: 1374853-91-4
1 KG Jan 2, 2025
Netherlands
pembrolizumab
1 KG Jan 2, 2025
South Korea
pembrolizumab
10 G Nov 28, 2024 Post an enquiry for this product